News

ABAC Therapeutics Announces €16 Million Series A to Develop Therapeutic Solutions to Fight Antibiotic-Resistant Bacteria

ABAC Therapeutics (ABAC), a leader in pathogen-specific antibiotics, announced today the closing of a €16 million Series A round. The financing was led by Pontifax with participation from the Global Health Science Fund (jointly established by Quark Venture Inc. and GF Securities), Caixa Capital Risc, Debiopharm Innovation Fund and the existing investor Ferrer.

| Read more |

QIAGEN enters into agreement to acquire STAT-Dx, a Caixa Capital Risc portfolio company

STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes. The system was unveiled in April 2017 at the European Congress of Clinical Microbiology (ECCMID) and received a first CE-IVD marking in January 2018.

| Read more |

Visual commerce platform Photoslurp receives €750K in investment

Photoslurp, the leading visual commerce platform in Europe, just received an investment of €750.000. Inveready Technology Investment Group, a leading VC in Spain, led the Photoslurp investment with participation from Bankinter VC (through the Entrepreneurship Programme of Bankinter’s Innvoation Foundation), Caixa Capital Risc and ICF. This is Photoslurp’s first investment, since the company was co-founded in 2014 by Ben Heinkel and Eulogi Bordas, having been completely bootstrapped to this point.

| Read more |

“la Caixa” and the Spanish Ministry of the Economy, Industry and Competitiveness, acting through Enisa, have announced a new edition of Premios EmprendedorXXI (EnterpriseXXI Awards), which go to the most innovative start-ups

”la Caixa”, acting through private equity management company Caixa Capital Risc, and the Spanish Ministry of the Economy, Industry and Competitiveness, for its part acting through Enisa, have just announced a new edition of the Premios EmprendedorXXI (EnterpriseXXI Awards). The event aims to name and support ground-breaking companies promising the greatest growth potential.

| Read more |

MedLumics, a company owned by “la Caixa” and Ysios Capital, closes a financing round of 34.4 million euros

• Medlumics has closed a round of financing round of 34,4 million euros to bring their main product into the market, AblaView, an atrial fibrillation treatment in the field of cardiac arrhythmias.
• Medlumics is a company dedicated to medical technology for the treatment of cardiac diseases, with products based on photonic energy.
• Caixa Capital Risc and Ysios Capital invested in Medlumics in 2012 to support the company in its development.
• This has been the largest round in the history of the medical technology industry in Spain, and one of the largest in Europe.

| Read more |